Search | Clinical Trials Finder

Conditions: Atrial Fibrillation
Interventions: Intravenous caffeine, Masked Placebo; Other
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 21 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Loma Linda, California • Overland Park, Kansas • Independence, Missouri + 2 more

Conditions: Orthostatic Hypotension, Falls
Interventions: Medication review, Nutrition/Salt intake, Education, Exercise, Drug Recommendations; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Gastroesophageal Reflux Disease
Interventions: 24-Hr Esohpageal pH Monitoring, PCO2 Acid Perfusion and 0.1N HCI Perfusion; Procedure
Lead sponsor: Southern Arizona VA Health Care System; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: HIV Infections
Interventions: DNA CON-S env, IHV01, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schistosomiasis
Interventions: Placebo, Sm-TSP-2/Alhydrogel, Sm-TSP-2/Alhydrogel/GLA-AF; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Syncytial Virus Infections
Interventions: MVA BN RSV, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Postoperative Pain, Total Knee Arthroplasty, Nerve Block
Interventions: bupivacaine, saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Healthy
Interventions: Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 669 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Stroke
Interventions: piclozotan low dose, placebo, piclozotan high dose; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more

Conditions: COVID-19
Interventions: Bronchoscopies and Bronchoalveolar Lavages (BALs), Chest Tomography (CT), Electrocardiogram (ECG), Pulmonary function tests (PFTs), 6 minute walk test (6MWT); Procedure · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: NasoShield, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions: BOTOX-A, Saline injection; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Peyronie Disease, Sexual Dysfunction, Physiological, Sexual Dysfunction Male, Genital Diseases, Male
Interventions: Autologous Platelet-Rich Plasma (PRP), Placebo (Normal Saline); Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab), Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 30
States / cities: Encinitas, California • Long Beach, California • Pasadena, California + 25 more

Conditions: Osteoarthritis, Post-traumatic; Arthrosis
Interventions: methylprednisolone acetate, active comparator; Drug
Lead sponsor: New Lexington Clinic; Other
Eligibility: 18 Years to 95 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Pain
Interventions: Intrathecal morphine injection, EXPAREL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 5
States / cities: Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more

Conditions: Neurocysticercosis
Interventions: Oxfendazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Sacroiliitis
Interventions: Active comparator: Fluoroscopic Guided SIJ injection, Ultrasound Guided Sacroiliac Joint Injection, Havel's Inc. EchoStim (facet tip) 21 Gauge 4" needle, SonoSite S-nerve, iohexol, triamcinolone/lidocaine; Procedure · Device · Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Wound Infection, Fractures, Open, Surgical Site Infection
Interventions: Tobramycin Injection; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Lexington, Kentucky • Boston, Massachusetts • Nashville, Tennessee

Conditions: Critical Limb Ischemia
Interventions: Low Dose VM202, High Dose VM202, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Orange, California • Chicago, Illinois + 9 more

Conditions: Influenza
Interventions: NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina

Conditions: West Nile Viral Infection
Interventions: HydroVax-001B WNV, Placebo, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Meniscus Tear, Meniscus Lesion, Cartilage Injury
Interventions: Ceftriaxone, Placebo; Drug · Other
Lead sponsor: Austin V Stone; Other
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction

Orthostatic Hypotension Treatment on Rehab Unit

The Effect of High PCO2 Solution on Esophageal Acid Sensation

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

US Guided GNB vs Saline Injection for TKA

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)

A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

NasoShield in Healthy Adults to Study Safety and Immunogenicity

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

PRP for Treatment of Peyronie's Disease

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole

Comparing the Effects of Ultrasound Versus Fluoroscopy for Sacroiliac Joint Injections

Tobramycin Injection to Prevent Infection in Open Fractures

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults

PROPER Trial of Pain and Inflammation After Knee Arthroscopy